Skip to main content
Clinical Trials/EUCTR2015-000654-38-NO
EUCTR2015-000654-38-NO
Active, not recruiting
Phase 1

Secondary prophylaxis after hip fracture. An evaluation og two organisational models based on choise of treatment: a comparison of efficacy and applicability of hospital based treatment with zoledronate versus primary care based treatment with denosumab

Akershus University Hospital, Norway0 sites500 target enrollmentMarch 23, 2015

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hip fracture
Sponsor
Akershus University Hospital, Norway
Enrollment
500
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 23, 2015
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Akershus University Hospital, Norway

Eligibility Criteria

Inclusion Criteria

  • 1\. Hip fracture patients 70 years of age or older treated at Akershus University Hospital during one year (365 days) and alive 6 weeks after the fracture. This encompasses also patients 70 years of age or older with a previous hip fracture who suffer a new hip fracture during the 365 days inclusion period
  • A hip fracture is defined as a fracture of the neck or the region of the femur. Hip fractures complicated by subtrochanteric fracture or femural shaft fracture are not included in this definition. Other fractures in combination with the hip fracture are allowed.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 500

Exclusion Criteria

  • 1\. Patients with estimated life expectancy less than 6 months
  • 2\. Patients unwilling to sign informed consent. Patients with reduced consent capabilities may participate if consent is provided by next of kin or legal guardian
  • 3\. Patients who have suffered allergic og hypersensitivity reactions to treatment with bisphosphonates or denosumab. Patients who have suffered reactions to one medication may partricipate if accepting treatment with the other.
  • 4\. Patients who are permanently bed\-ridden.
  • 5\. Patients who due to other disease are not considered candidates for study participation.
  • 6\. Patients with history of osteonecrosis of the jaw or atypical femural fractures.

Outcomes

Primary Outcomes

Not specified

Similar Trials